Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-28
1999-01-05
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31495
Patent
active
058563296
ABSTRACT:
A method according to which neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula I to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death ##STR1## wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substitutent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy is disclosed.
REFERENCES:
patent: 4029792 (1977-06-01), Danielewicz et al.
patent: 5180721 (1993-01-01), Burke
patent: 5215991 (1993-06-01), Burke
Schumer et al, "The Nerve of Glaucoma|", Arch. Ophthalmol. vol. 112, Jan. 1994, pp. 37-44.
Barnebey et al., "The Efficacy of Brimonidine in Decreasing Elevations in Intraocular Pressure after Laser Trabeculoplasty", Ophthalmology, 100(7) Jul. 1993, 1083-1088.
David, et al., "Brimonidine in the Prevention of Intraocular Pressure Elevation Following Argon Laser Trabeculoplasty", Arch Ophthalmol, vol. 111, Oct. 1993, 1287-1390.
Janet B. Serle, "Pharmacological Advances in the Treatment of Glaucoma", Drugs Aging, 5 (3), Sep. 1994, 156-170.
E. Yales, et al., "Injury-Induced Secondary Degeneration of Rat Optic Nerve Can Be Attenuated by .alpha.2/Adrenoceptor Agonists AGN 191103 and Brimonidine" Investigative Ophthalmology and Visual Science, 37 (3), 1996, S114.
Sabel et al, "Functional Recovery and Morphological Changes after Injury to the Optic Nerve", Neuropsychobiology 1993; 28: 62-65.
Stys et al, "Compound action potential of nerve recorded by suction electrode: a theoretical and experimental analysis", Brain Research, 546 (1991) pp. 18-32.
Burke et al, "Ocular effects of a relatively selective .alpha.2 agonist (UK-14, 304-18) in cats, rabbits and monkeys", Current Eye Research, vol. 5, No. 9, 1986, pp. 665-676.
Michel et al, "Keeping an eye on the I site: imidazoline-preferring
Chemical Abstracts 122: 96456 (1994). Gablet et al.
Lai Ronald K.
Wheeler Larry A.
WoldeMussie Elizabeth
Allergan
Baran Robert J.
Fay Zohreh
Hoch James M.
Voet Martin A.
LandOfFree
Method of using (2-imidazolin-2-ylamino) quinoxalines in treatin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using (2-imidazolin-2-ylamino) quinoxalines in treatin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using (2-imidazolin-2-ylamino) quinoxalines in treatin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-862548